MOTS-c for Energy: What the Evidence Shows
The mitochondrial-derived peptide MOTS-c is being promoted online as an energy enhancer, but published research is still at the proof-of-concept stage. Here is what the science, not the hype, actually says.
MOTS-c is a 16-amino-acid microprotein made inside mitochondria that signals when a cell is under metabolic stress, turning on genes that help it use fuel more efficiently. Animal studies show that giving extra MOTS-c can improve exercise capacity, but the only human data so far connect natural MOTS-c blood levels with body fat and metabolic traits, not with felt energy. No clinical trials have tested whether a MOTS-c injection makes people feel less tired, so energy claims are speculative, and the peptide remains experimental.
- MOTS-c is encoded within the mitochondrial 12S rRNA and belongs to a family of mitochondrial-derived peptides that act as metabolic stress signals (Merry et al., 2020).
- High-intensity exercise acutely raises skeletal-muscle and plasma MOTS-c in humans, hinting that the peptide helps coordinate the workout recovery response (Woodhead et al., 2021).
- In mice, exogenous MOTS-c activates AMPK and PGC-1α pathways and improves treadmill performance, indicating potential effects on mitochondrial fitness (Woodhead et al., 2021) (Gudiksen et al., 2026).
- The FDA’s 2026 interim “access policy” lets 503A pharmacies compound MOTS-c for individual patients who have a prescription, but the peptide itself is not FDA-approved as a drug.
- Rx.com plans to offer prescription compounded versions of MOTS-c, BPC-157, TB-500, KPV, Semax, and Epitalon through U.S.-licensed providers and a licensed 503A pharmacy (coming soon).
What MOTS-c Is
MOTS-c is a mitochondrial-derived peptide (MDP): a 16-amino-acid microprotein encoded by a short open-reading frame inside the mitochondrial 12S rRNA gene (Merry et al., 2020). It is produced inside the cell’s powerhouses and then moves to the nucleus to adjust gene expression when energy supply is low. Researchers classify MOTS-c with other MDPs such as humanin and SHLPs that help cells adapt to metabolic stress (Mustafa et al., 2026).
Definition (50 words): MOTS-c is a naturally occurring microprotein made by human mitochondria that senses cellular energy stress, activates AMP-activated protein kinase (AMPK), and re-programs nuclear genes to improve glucose and fat metabolism.
How MOTS-c May Influence Energy
Laboratory work suggests MOTS-c turns on master regulators of mitochondrial health.
AMPK activation: In muscle cells and mouse models, MOTS-c rapidly activates AMPK, the cellular “fuel gauge” that ramps up glucose uptake and fatty-acid oxidation (Gudiksen et al., 2026).
PGC-1α signaling: Downstream, AMPK boosts PGC-1α, a co-activator that increases mitochondrial number and function. Mice given MOTS-c showed improved mitochondrial bioenergetic efficiency and lower reactive-oxygen species generation (Gudiksen et al., 2026).
Exercise mimic? Because intense workouts also trigger AMPK-PGC-1α signaling, some scientists consider MOTS-c a potential “exercise mimetic,” but that remains hypothetical (Woodhead et al., 2021) (Ayubi et al., 2026).
What Animal Studies Show
Most evidence for MOTS-c and physical performance comes from rodent experiments.
Improved endurance: Young and aged mice receiving MOTS-c performed better on treadmill tests than untreated controls (Woodhead et al., 2021). Exact distance gains vary across studies and are not provided in published abstracts.
Metabolic health benefits: Separate rodent work links MOTS-c treatment with enhanced insulin sensitivity and protection against diet-induced obesity (Merry et al., 2020) (Fang et al., 2025).
| Preclinical outcome | Effect of MOTS-c | Primary source |
|---|---|---|
| Treadmill performance in mice | Improved endurance and recovery | (Woodhead et al., 2021) |
| Muscle mitochondrial efficiency | Higher bioenergetic performance, lower ROS | (Gudiksen et al., 2026) |
| Insulin sensitivity | Enhanced glucose tolerance | (Merry et al., 2020) |
What Human Data Tell Us
Human evidence is limited to observational measurements and short-term exercise trials.
Waist circumference showed the strongest positive association with circulating MOTS-c (p < 0.0001) (Sequeira et al., 2021).
| Group | N | Mean plasma MOTS-c (pg/ml) |
|---|---|---|
| No metabolic syndrome | 99 | Approx. 295 |
| Metabolic syndrome | 26 | 315 ± 27 |
Exercise response: Acute high-intensity cycling and running raised skeletal-muscle and plasma MOTS-c in small volunteer studies, suggesting the peptide is part of the immediate stress response to exercise (Woodhead et al., 2021). However, whether higher levels translate into better felt energy or performance in people is unknown.
Systematic review: A 2026 systematic review found only nine exercise-and-MDP human studies worldwide, highlighting how early the field is (Ayubi et al., 2026). None were randomized clinical trials of exogenous MOTS-c.
Why Energy Claims Outrun Evidence
No clinical trials in humans: To date, no peer-reviewed trial has given people MOTS-c and measured energy, fatigue scores, or athletic performance.
Observational does not prove causation: Higher circulating MOTS-c in individuals with more abdominal fat may reflect a compensatory response, not a cause of higher energy (Sequeira et al., 2021).
Mouse doses ≠ human doses: The amounts used in rodent studies have not been scaled for people, and safety in long-term human use is unknown.
Marketing leap: Supplement sellers sometimes cite rodent treadmill data as proof of an “energy peptide,” but such extrapolation ignores species differences and the absence of human outcomes.
⚠️ Evidence gap
Until rigorously controlled human studies report actual improvements in fatigue, VO2 max, or time-to-exhaustion, any promise that a MOTS-c injection will make you feel more energetic is speculative.
Safety, Regulation and Access
Not FDA-approved: MOTS-c is not an FDA-approved drug for any indication. No manufacturer has filed a New Drug Application or biologics license.
Interim compounding policy: In 2026 the U.S. Department of Health and Human Services issued an interim enforcement-discretion policy that allows state-licensed 503A pharmacies to compound MOTS-c for individual patients who hold a prescription, provided the pharmacy meets ingredient quality, manufacturing, labeling and safety-reporting conditions. The policy is temporary and does not constitute FDA approval.
Variability across states: State boards of pharmacy are not required to follow the policy. Some may still restrict or prohibit compounding of MOTS-c or other unapproved peptides.
Research-use-only pitfalls: Products sold online as “not for human use” fall outside the policy and lack quality controls. Buying or injecting them carries unknown purity and dosing risks.
Prescription access coming soon: Rx.com plans to offer prescription compounded versions of MOTS-c through U.S.-licensed providers and a 503A pharmacy (coming soon). Learn more at prescription peptides from Rx.com.
For more on regulatory background, see our detailed guide to the FDA peptide compounding policy and how the 503A bulks list works.
Should you discuss MOTS-c with a healthcare provider?
Check the column that fits your situation:
✅ Might be reasonable
- You are enrolled in a supervised clinical study that includes MOTS-c
- You understand the peptide is experimental and unapproved
- You are willing to monitor labs and report side effects promptly
- You cannot engage in vigorous exercise because of physical limitations
🏥 Best to avoid or delay
- You plan to self-inject research-grade MOTS-c bought without a prescription
- You have active cancer or a history of cancer under evaluation
- You are pregnant, breastfeeding or trying to conceive
- You expect guaranteed energy boosts or weight loss
| Research landscape (2026) | Number of publications | Main takeaway |
|---|---|---|
| Animal studies with exogenous MOTS-c | 20 + | Consistent metabolic benefits in rodents (Merry et al., 2020) (Woodhead et al., 2021) (Gudiksen et al., 2026) |
| Human exercise-response studies | 9 | MOTS-c rises acutely after intense exercise (Ayubi et al., 2026) |
| Human observational datasets | 1 major (n = 125) | Higher MOTS-c associated with larger waist circumference (Sequeira et al., 2021) |
| Randomized controlled trials of exogenous MOTS-c in humans | 0 | No efficacy or safety data yet |
🚨 When to Contact Your Healthcare Provider
Seek medical advice immediately if you:
- Develop sudden chest pain or shortness of breath, which could signal a cardiac event unrelated to peptide use but needing urgent care.
- Notice swelling, redness or pain at an injection site, suggesting infection or sterile abscess formation.
- Experience severe fatigue, dizziness or fainting, indicating possible metabolic or cardiovascular effects.
- Have unexplained rapid weight gain or swelling, which may reflect fluid retention or kidney stress.
- See dark urine or jaundice, potential signs of liver injury.
- Develop a rash, itching or hives, which could mean an allergic reaction.
- Feel new or worsening anxiety, agitation or mood changes, because mitochondrial peptides may interact with stress pathways.
- Plan any elective surgery and are using experimental peptides, so your surgical team can coordinate care.
Scientific References
- Merry TL, Chan A, Woodhead JST, et al. Mitochondrial-derived peptides in energy metabolism. Am J Physiol Endocrinol Metab. 2020.
- Woodhead JST, Merry TL. Mitochondrial-derived peptides and exercise. Biochim Biophys Acta Gen Subj. 2021.
- Gudiksen A, Hansen CC, van der Stede T, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1α/AMPK-dependent manner. Free Radic Biol Med. 2026.
- Mustafa AM, Ali RM, Omar SS, et al. Emerging regulators of human physiology and disease; sORF-encoded microproteins. Epigenomics. 2026.
- Ayubi N, Wibawa JC, Kurnaz M, et al. Mitochondrial-derived peptides (MDPs) activated by physical exercise as therapeutic targets for metabolic disorders: A systematic review. Physiol Int. 2026.
- Fang T, Han JC, Taberner A, et al. MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment. Life Sci. 2025.
- Sequeira IR, Woodhead JST, Chan A, et al. Plasma mitochondrial derived peptides MOTS-c and SHLP2 positively associate with android and liver fat in people without diabetes. Biochim Biophys Acta Gen Subj. 2021.
Frequently Asked Questions
Is MOTS-c the same as humanin?
No. Both are mitochondrial-derived peptides, but MOTS-c is a 16-amino-acid peptide from the 12S rRNA gene, whereas humanin is a 24-amino-acid peptide encoded in the 16S rRNA region (Merry et al., 2020).
Does MOTS-c help with weight loss?
Rodent studies link MOTS-c with better insulin sensitivity and resistance to diet-induced obesity (Merry et al., 2020). Human trials have not tested weight loss, so no conclusion can be drawn.
Can I buy MOTS-c legally online?
Only a prescription compounded MOTS-c prepared by a state-licensed 503A pharmacy under the FDA interim policy fits within U.S. law. “Research use only” vials sold online are not meant for people and fall outside quality-control oversight.
How is MOTS-c different from NAD+ or NAD+ injections?
NAD+ is a metabolic coenzyme, while MOTS-c is a signaling peptide that activates AMPK. They act on overlapping energy pathways but are chemically distinct and studied separately.
Is MOTS-c banned in sports?
The World Anti-Doping Agency (WADA) has not issued a specific ruling on MOTS-c, but any unapproved performance-enhancing substance could violate anti-doping rules. Athletes should consult their governing body.
What dose of MOTS-c do mice receive in studies?
Individual animal protocols vary and are not standardized. Published abstracts do not list precise dosing schedules, highlighting why mouse data cannot be directly translated to people.
Could MOTS-c be combined with TB-500 or other peptides?
Combination “stacks” popular on forums have no human safety data. Each peptide remains experimental, and mixing them increases unknown risk.
Where can I learn more about prescription peptide regulations?
See our article “Peptide regulations: what buyers should know.” It breaks down the FDA interim policy and state-level considerations in plain language.
